Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2010 Dec 22;684:57–68. doi: 10.1007/978-1-4419-6451-9_5

The Role of OX40 (CD134) in T-Cell Memory Generation

Andrew D Weinberg ‡,✉
Editors: Maurizio Zanetti6, Stephen P Schoenberger7
PMCID: PMC7123855  PMID: 20795540

Abstract

Memory T-cell generation is limited by activation-induced cell death during the effector T-cell stage. Cell surface proteins are known to transmit signals that either accentuate or limit T-cell death after activation. This chapter will focus on the TNF-receptor family member OX40, which is expressed on effector T cells and when engaged greatly enhances survival of T cells leading to increased memory T-cell generation. Targeting OX40 in vivo can alter the fate of T-cell survival. Enhancing OX40 signaling during Ag priming through agonists increases memory T-cell development, while blocking OX40 signaling decreases the memory T-cell pool. These two opposing outcomes provide therapeutic tools for blocking inflammation in autoimmune conditions and enhancing immunity in hosts harboring cancer or chronic pathogens. OX40 agonists and antagonists are in the first stages of human clinical trials and their therapeutic potential will soon be realized.

Keywords: West Nile Virus, Human Airway Smooth Muscle, OX40 Ligand, Innate Cytokine, OX40 Expression

References

  • 1.Dutton R.W., Bradley L.M., Swain S.L. T-cell memory. Annu Rev Immunol. 1998;16:201–23. doi: 10.1146/annurev.immunol.16.1.201. [DOI] [PubMed] [Google Scholar]
  • 2.Redmond W.L., Weinberg A.D. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol. 2007;27(5):415–36. doi: 10.1615/critrevimmunol.v27.i5.20. [DOI] [PubMed] [Google Scholar]
  • 3.Maxwell J.R., Weinberg A., Prell R.A., et al. Danger and OX40 receptor signaling synergize to enhance memory T-cell survival by inhibiting peripheral deletion. J Immunol. 2000;164(1):107–12. doi: 10.4049/jimmunol.164.1.107. [DOI] [PubMed] [Google Scholar]
  • 4.Evans D.E., Prell R.A., Thalhofer C.J., et al. Engagement of OX40 enhances antigen-specific CD4(+) T-cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol. 2001;167(12):6804–11. doi: 10.4049/jimmunol.167.12.6804. [DOI] [PubMed] [Google Scholar]
  • 5.Ruby C.E., Redmond W.L., Haley D., et al. Anti-OX40 stimulation in vivo enhances CD8(+) memory T-cell survival and significantly increases recall responses. Eur J Immunol. 2007;37(1):157–66. doi: 10.1002/eji.200636428. [DOI] [PubMed] [Google Scholar]
  • 6.Pippig S.D., Pena-Rossi C., Long J., et al. Robust B-cell immunity but impaired T-cell proliferation in the absence of CD134 (OX40) J Immunol. 1999;163(12):6520–9. [PubMed] [Google Scholar]
  • 7.Rogers P.R., Song J., Gramaglia I., et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T-cells. Immunity. 2001;15(3):445–55. doi: 10.1016/S1074-7613(01)00191-1. [DOI] [PubMed] [Google Scholar]
  • 8.Baum P.R., Gayle R.B., 3rd, Ramsdell F., et al. Molecular characterization of murine and human OX40/ OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994;13(17):3992–4001. doi: 10.1002/j.1460-2075.1994.tb06715.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Paterson D.J., Jefferies W.A., Green J.R., et al. Antigens of activated rat T-lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987;24(12):1281–90. doi: 10.1016/0161-5890(87)90122-2. [DOI] [PubMed] [Google Scholar]
  • 10.Takeda I., Ine S., Killeen N., et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T-cells. J Immunol. 2004;172(6):3580–9. doi: 10.4049/jimmunol.172.6.3580. [DOI] [PubMed] [Google Scholar]
  • 11.Gramaglia I., Weinberg A.D., Lemon M., et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T-cell responses. J Immunol. 1998;161(12):6510–7. [PubMed] [Google Scholar]
  • 12.Weinberg A.D., Celnik B., Vainiene M., et al. The effect of TCR V beta 8 peptide protection and therapy on T-cell populations isolated from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol. 1994;49(1–2):161–70. doi: 10.1016/0165-5728(94)90192-9. [DOI] [PubMed] [Google Scholar]
  • 13.Buenafe A.C., Weinberg A.D., Culbertson N.E., et al. V beta CDR3 motifs associated with BP recognition are enriched in OX-40 + spinal cord T-cells of Lewis rats with EAE. J Neurosci Res. 1996;44(6):562–7. doi: 10.1002/(SICI)1097-4547(19960615)44:6<562::AID-JNR6>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 14.Weinberg A.D., Rivera M.M., Prell R., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol. 2000;164(4):2160–9. doi: 10.4049/jimmunol.164.4.2160. [DOI] [PubMed] [Google Scholar]
  • 15.Weinberg A.D., Bourdette D.N., Sullivan T.J., et al. Selective depletion of myelin-reactive T-cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 1996;2(2):183–9. doi: 10.1038/nm0296-183. [DOI] [PubMed] [Google Scholar]
  • 16.Weinberg A.D. OX40: targeted immunotherapy—implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002;23(2):102–9. doi: 10.1016/S1471-4906(01)02127-5. [DOI] [PubMed] [Google Scholar]
  • 17.Ramstad T., Lawnicki L., Vetto J., et al. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg. 2000;179(5):400–6. doi: 10.1016/S0002-9610(00)00361-5. [DOI] [PubMed] [Google Scholar]
  • 18.Vetto J.T., Lum S., Morris A., et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 1997;174(3):258–65. doi: 10.1016/S0002-9610(97)00139-6. [DOI] [PubMed] [Google Scholar]
  • 19.Martin P.J., Ledbetter J.A., Morishita Y., et al. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T-lymphocytes. J Immunol. 1986;136(9):3282–7. [PubMed] [Google Scholar]
  • 20.Jenkins M.K., Mueller D., Schwartz R.H., et al. Induction and maintenance of anergy in mature T-cells. Adv Exp Med Biol. 1991;292:167–76. doi: 10.1007/978-1-4684-5943-2_19. [DOI] [PubMed] [Google Scholar]
  • 21.Harding F.A., McArthur J.G., Gross J.A., et al. CD28-mediated signalling costimulates murine T-cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607–9. doi: 10.1038/356607a0. [DOI] [PubMed] [Google Scholar]
  • 22.Kaleeba J.A., Offner H., Vandenbark A.A., et al. The OX-40 receptor provides a potent costimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T-cells. Int Immunol. 1998;10(4):453–61. doi: 10.1093/intimm/10.4.453. [DOI] [PubMed] [Google Scholar]
  • 23.Lenschow D.J., Walunas T.L., Bluestone J.A. CD28/B7 system of T-cell costimulation. Annu Rev Immunol 1996; 14:233-58. 24._Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T-cell stage. Semin Immunol. 1998;10(6):471–80. doi: 10.1006/smim.1998.0146. [DOI] [PubMed] [Google Scholar]
  • 25.Stuber E., Neurath M., Calderhead D., et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B-cells. Immunity. 1995;2(5):507–21. doi: 10.1016/1074-7613(95)90031-4. [DOI] [PubMed] [Google Scholar]
  • 26.Stuber E., Strober W. The T-cell-B-cell interaction via OX40-OX40L is necessary for the T-cell-dependent humoral immune response. J Exp Med. 1996;183(3):979–89. doi: 10.1084/jem.183.3.979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Murata K., Nose M., Ndhlovu L.C., et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol. 2002;169(8):4628–36. doi: 10.4049/jimmunol.169.8.4628. [DOI] [PubMed] [Google Scholar]
  • 28.Miura S., Ohtani K., Numata N., et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol. 1991;11(3):1313–25. doi: 10.1128/mcb.11.3.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Godfrey W.R., Fagnoni F.F., Harara M.A., et al. Identification of a human OX-40 ligand, a costimulator of CD4+ T-cells with homology to tumor necrosis factor. J Exp Med. 1994;180(2):757–62. doi: 10.1084/jem.180.2.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Imura A., Hori T., Imada K., et al. The human OX40/gp34 system directly mediates adhesion of activated T-cells to vascular endothelial cells. J Exp Med. 1996;183(5):2185–95. doi: 10.1084/jem.183.5.2185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Calderhead D.M., Buhlmann J.E., van den Eertwegh A.J., et al. Cloning of mouse Ox40: a T-cell activation marker that may mediate T-B-cell interactions. J Immunol. 1993;151(10):5261–71. [PubMed] [Google Scholar]
  • 32.Ohshima Y., Tanaka Y., Tozawa H., et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48. [PubMed] [Google Scholar]
  • 33.Sato T., Ishii N., Murata K., et al. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. Eur J Immunol. 2002;32(11):3326–35. doi: 10.1002/1521-4141(200211)32:11<3326::AID-IMMU3326>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 34.Zingoni A., Sornasse T., Cocks B.G., et al. Cross-talk between activated human NK cells and CD4+ T-cells via OX40-OX40 ligand interactions. J Immunol. 2004;173(6):3716–24. doi: 10.4049/jimmunol.173.6.3716. [DOI] [PubMed] [Google Scholar]
  • 35.Akiba H., Oshima H., Takeda K., et al. CD28-independent costimulation of T-cells by OX40 ligand and CD70 on activated B-cells. J Immunol. 1999;162(12):7058–66. [PubMed] [Google Scholar]
  • 36.Burgess J.K., Carlin S., Pack R.A., et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Immunol. 2004;113(4):683–9. doi: 10.1016/j.jaci.2003.12.311. [DOI] [PubMed] [Google Scholar]
  • 37.Weinberg A.D., Wegmann K.W., Funatake C., et al. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999;162(3):1818–26. [PubMed] [Google Scholar]
  • 38.Kim M.Y., Gaspal F.M., Wiggett H.E., et al. CD4(+)CD3(−) accessory cells costimulate primed CD4 T-cells through OX40 and CD30 at sites where T-cells collaborate with B-cells. Immunity. 2003;18(5):643–54. doi: 10.1016/S1074-7613(03)00110-9. [DOI] [PubMed] [Google Scholar]
  • 39.Brocker T., Gulbranson-Judge A., Flynn S., et al. CD4 T-cell traffic control: in vivo evidence that ligation of OX40 on CD4 T-cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T-cells in B follicles. Eur J Immunol. 1999;29(5):1610–6. doi: 10.1002/(SICI)1521-4141(199905)29:05<1610::AID-IMMU1610>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  • 40.Soroosh P., Ine S., Sugamura K., et al. OX40-OX40 ligand interaction through T-cell-T-cell contact contributes to CD4 T-cell longevity. J Immunol. 2006;176(10):5975–87. doi: 10.4049/jimmunol.176.10.5975. [DOI] [PubMed] [Google Scholar]
  • 41.Murata K., Ishii N., Takano H., et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med. 2000;191(2):365–74. doi: 10.1084/jem.191.2.365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kopf M., Ruedl C., Schmitz N., et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B-cell and CTL Responses after virus infection. Immunity. 1999;11(6):699–708. doi: 10.1016/S1074-7613(00)80144-2. [DOI] [PubMed] [Google Scholar]
  • 43.Gramaglia I., Jember A., Pippig S.D., et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165(6):3043–50. doi: 10.4049/jimmunol.165.6.3043. [DOI] [PubMed] [Google Scholar]
  • 44.Jember A.G., Zuberi R., Liu F.T., et al. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med. 2001;193(3):387–92. doi: 10.1084/jem.193.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Salek-Ardakani S., Song J., Halteman B.S., et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med. 2003;198(2):315–24. doi: 10.1084/jem.20021937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251–62. doi: 10.1038/nri778. [DOI] [PubMed] [Google Scholar]
  • 47.Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78(11):5535–45. doi: 10.1128/JVI.78.11.5535-5545.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wherry E.J., Teichgraber V., Becker T.C., et al. Lineage relationship and protective immunity of memory CD8 T-cell subsets. Nat Immunol. 2003;4(3):225–34. doi: 10.1038/ni889. [DOI] [PubMed] [Google Scholar]
  • 49.Soroosh P., Ine S., Sugamura K., et al. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T-cells. J Immunol. 2007;179(8):5014–23. doi: 10.4049/jimmunol.179.8.5014. [DOI] [PubMed] [Google Scholar]
  • 50.Song A., Tang X., Harms K.M., et al. OX40 and Bcl-xL promote the persistence of CD8 T-Cells to recall tumor-associated antigen. J Immunol. 2005;175(6):3534–41. doi: 10.4049/jimmunol.175.6.3534. [DOI] [PubMed] [Google Scholar]
  • 51.Hendriks J., Xiao Y., Rossen J.W., et al. During viral infection of the respiratory tract, CD27, 4-1BB and OX40 collectively determine formation of CD8+ memory T-cells and their capacity for secondary expansion. J Immunol. 2005;175(3):1665–76. doi: 10.4049/jimmunol.175.3.1665. [DOI] [PubMed] [Google Scholar]
  • 52.Melero I., Hervas-Stubbs S., Glennie M., et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95–106. doi: 10.1038/nrc2051. [DOI] [PubMed] [Google Scholar]
  • 53.Prell R.A., Evans D.E., Thalhofer C., et al. OX40-mediated memory T-cell generation is TNF receptor-associated factor 2 dependent. J Immunol. 2003;171(11):5997–6005. doi: 10.4049/jimmunol.171.11.5997. [DOI] [PubMed] [Google Scholar]
  • 54.Ruby C.E., Montler R., Zheng R., et al. IL-12 is required for anti-OX40-mediated CD4 T-cell survival. J Immunol. 2008;180(4):2140–8. doi: 10.4049/jimmunol.180.4.2140. [DOI] [PubMed] [Google Scholar]
  • 55.Redmond W.L., Gough M.J., Charbonneau B., et al. Defects in the Acquisition of CD8 T-Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist. J Immunol. 2007;179(11):7244–53. doi: 10.4049/jimmunol.179.11.7244. [DOI] [PubMed] [Google Scholar]
  • 56.Baumann R., Yousefi S., Simon D., et al. Functional expression of CD134 by neutrophils. Eur J Immunol. 2004;34(8):2268–75. doi: 10.1002/eji.200424863. [DOI] [PubMed] [Google Scholar]
  • 57.Sugamura K., Ishii N., Weinberg A.D. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol. 2004;4(6):420–31. doi: 10.1038/nri1371. [DOI] [PubMed] [Google Scholar]
  • 58.Sadun R.E., Hsu W.E., Zhang N., et al. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother. 2008;31(3):235–45. doi: 10.1097/CJI.0b013e31816a88e0. [DOI] [PubMed] [Google Scholar]
  • 59.Kjaergaard J., Tanaka J., Kim J.A., et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514–21. [PubMed] [Google Scholar]
  • 60.Kjaergaard J., Peng L., Cohen P.A., et al. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 2001;167(11):6669–77. doi: 10.4049/jimmunol.167.11.6669. [DOI] [PubMed] [Google Scholar]
  • 61.Gri G., Gallo E., Di Carlo E., et al. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T-cell antitumor response. J Immunol. 2003;170(1):99–106. doi: 10.4049/jimmunol.170.1.99. [DOI] [PubMed] [Google Scholar]
  • 62.Murata S., Ladle B.H., Kim P.S., et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T-cell tolerance to an endogenous tumor antigen. J Immunol. 2006;176(2):974–83. doi: 10.4049/jimmunol.176.2.974. [DOI] [PubMed] [Google Scholar]
  • 63.Humphreys I.R., de Trez C., Kinkade A., et al. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med. 2007;204(5):1217–25. doi: 10.1084/jem.20062424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Humphreys I.R., Loewendorf A., de Trez C., et al. OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T-Cells: A CD4-dependent mechanism. J Immunol. 2007;179(4):2195–202. doi: 10.4049/jimmunol.179.4.2195. [DOI] [PubMed] [Google Scholar]
  • 65.Humphreys I.R., Edwards L., Walzl G., et al. OX40 ligation on activated T-cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol. 2003;170(12):6125–32. doi: 10.4049/jimmunol.170.12.6125. [DOI] [PubMed] [Google Scholar]
  • 66.Weinberg A.D., Thalhofer C., Morris N., et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother. 2006;29(6):575–85. doi: 10.1097/01.cji.0000211319.00031.fc. [DOI] [PubMed] [Google Scholar]

Articles from Memory T Cells are provided here courtesy of Nature Publishing Group

RESOURCES